SARS-CoV-2 nsp14-IN-1

• UNSPSC Description:

  SARS-CoV-2 nsp14-IN-1 (Compound 3) is a prototypic bisubstrate inhibitor of SARS-CoV-2 Nsp14 MTase with an IC50 value of 0.061 μM. SARS-CoV-2 nsp14-IN-1 (Compound 3) has an excellent selectivity profile over a panel of human methyltransferases, can against apanel of 10 human MTases including histone lysine, proteinarginine, and DNA and RNA MTases[1].

• Target Antigen:

  DNA Methyltransferase; Histone Methyltransferase; SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Epigenetics

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/sars-cov-2-nsp14-in-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=S(C1=CC=C2C=CC=CC2=C1)(NC[C@H]3O[C@@H](N4C=NC5=C(N)N=CN=C45)[C@H](O)[C@@H]3O)=O

• Molecular Weight:

  456.48

• References & Citations:

  [1]Eunkyung Jung, et al. Bisubstate Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 Nsp14 Methyltransferase. ACS Med. Chem. Lett. July 22, 2022.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2816165-02-1